In this report, our team research the global Ophthalmic Drugs market by type, application, region and manufacturer 2014-2019 and forcast 2020-2025. For the region, type and application, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Ophthalmic Drugs in these regions, from 2012 to 2023 (forecast), covering
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
South America (Brazil, Argentina, Columbia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Global Ophthalmic Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Pfizer
Merck
Glaxosmithkline
Abbott Laboratories
Johnson and Johnson
Bayer
Shire
Roche Holding
Novartis
Akorn
Eyemed
Senju Pharmaceutical
Sun Pharmaceuticals Industries
Allergan
Valeant
Regeneron
Eyegate Pharmaceuticals
Lpath Incorporated
Santen Pharmaceutical
Cipla Pharmaceuticals
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Solutions
Ointments
Other
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Ophthalmic Drugs for each application, including
Hospital Pharmacies
Online Pharmacies
Independent Pharmacies & Drug Stores
If you have any special requirements, please let us know and we will offer you the report as you want.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Ophthalmic Drugs Market, By Drug Class
7.1. Ophthalmic Drugs Market, By Drug Class, 2020-2030
7.1.1. Antiallergy
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Anti-VEGF Agents
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Anti-inflammatory
7.1.3.1. Market Revenue and Forecast (2016-2030)
7.1.4. Antiglaucoma
7.1.4.1. Market Revenue and Forecast (2016-2030)
7.1.5. Others
7.1.5.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Ophthalmic Drugs Market, By Disease
8.1. Ophthalmic Drugs Market, By Disease, 2020-2030
8.1.1. Dry Eye
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Eye Allergy
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Glaucoma
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Eye Infection
8.1.4.1. Market Revenue and Forecast (2016-2030)
8.1.5. Retinal Disorders
8.1.5.1. Market Revenue and Forecast (2016-2030)
8.1.6. Uveitis
8.1.6.1. Market Revenue and Forecast (2016-2030)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Ophthalmic Drugs Market, By Dosage Form Type
9.1. Ophthalmic Drugs Market, By Dosage Form Type, 2020-2030
9.1.1. Gels
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Eye Solutions
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. Capsules & Tablets
9.1.3.1. Market Revenue and Forecast (2016-2030)
9.1.4. Eye Drops
9.1.4.1. Market Revenue and Forecast (2016-2030)
9.1.5. Ointments
9.1.5.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Ophthalmic Drugs Market, By Route of Administration Type
10.1. Ophthalmic Drugs Market, By Route of Administration Type, 2020-2030
10.1.1. Topical
10.1.1.1. Market Revenue and Forecast (2016-2030)
10.1.2. Local Ocular
10.1.2.1. Market Revenue and Forecast (2016-2030)
10.1.3. Systemic
10.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 11. Global Ophthalmic Drugs Market, By Product Type
11.1. Ophthalmic Drugs Market, By Product Type, 2020-2030
11.1.1. Prescription Drugs
11.1.1.1. Market Revenue and Forecast (2016-2030)
11.1.2. OTC Drugs
11.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 12. Global Ophthalmic Drugs Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.1.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.1.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.1.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.1.5. Market Revenue and Forecast, By Product Type (2016-2030)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.1.6.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.1.6.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.1.6.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.1.7. Market Revenue and Forecast, By Product Type (2016-2030)
12.1.8. Rest of North America
12.1.8.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.1.8.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.1.8.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.1.8.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.1.8.5. Market Revenue and Forecast, By Product Type (2016-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.2.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.2.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.2.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.2.5. Market Revenue and Forecast, By Product Type (2016-2030)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.2.6.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.2.6.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.2.7. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.2.8. Market Revenue and Forecast, By Product Type (2016-2030)
12.2.9. Germany
12.2.9.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.2.9.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.2.9.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.2.10. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.2.11. Market Revenue and Forecast, By Product Type (2016-2030)
12.2.12. France
12.2.12.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.2.12.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.2.12.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.2.12.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.2.13. Market Revenue and Forecast, By Product Type (2016-2030)
12.2.14. Rest of Europe
12.2.14.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.2.14.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.2.14.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.2.14.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.2.15. Market Revenue and Forecast, By Product Type (2016-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.3.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.3.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.3.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.3.5. Market Revenue and Forecast, By Product Type (2016-2030)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.3.6.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.3.6.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.3.6.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.3.7. Market Revenue and Forecast, By Product Type (2016-2030)
12.3.8. China
12.3.8.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.3.8.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.3.8.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.3.8.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.3.9. Market Revenue and Forecast, By Product Type (2016-2030)
12.3.10. Japan
12.3.10.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.3.10.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.3.10.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.3.10.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.3.10.5. Market Revenue and Forecast, By Product Type (2016-2030)
12.3.11. Rest of APAC
12.3.11.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.3.11.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.3.11.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.3.11.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.3.11.5. Market Revenue and Forecast, By Product Type (2016-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.4.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.4.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.4.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.4.5. Market Revenue and Forecast, By Product Type (2016-2030)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.4.6.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.4.6.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.4.6.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.4.7. Market Revenue and Forecast, By Product Type (2016-2030)
12.4.8. North Africa
12.4.8.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.4.8.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.4.8.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.4.8.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.4.9. Market Revenue and Forecast, By Product Type (2016-2030)
12.4.10. South Africa
12.4.10.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.4.10.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.4.10.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.4.10.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.4.10.5. Market Revenue and Forecast, By Product Type (2016-2030)
12.4.11. Rest of MEA
12.4.11.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.4.11.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.4.11.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.4.11.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.4.11.5. Market Revenue and Forecast, By Product Type (2016-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.5.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.5.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.5.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.5.5. Market Revenue and Forecast, By Product Type (2016-2030)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.5.6.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.5.6.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.5.6.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.5.7. Market Revenue and Forecast, By Product Type (2016-2030)
12.5.8. Rest of LATAM
12.5.8.1. Market Revenue and Forecast, By Drug Class type (2016-2030)
12.5.8.2. Market Revenue and Forecast, By Disease Type (2016-2030)
12.5.8.3. Market Revenue and Forecast, By Dosage Form Type (2016-2030)
12.5.8.4. Market Revenue and Forecast, By Route of Administration (2016-2030)
12.5.8.5. Market Revenue and Forecast, By Product Type (2016-2030)
Chapter 13. Company Profiles
13.1. Alcon
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Johnson & Johnson Services, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Bausch Health
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Allergan
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Pfizer, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Bayer AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Santen Pharmaceutical Co. Ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Genentech, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novartis AG.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Regeneron
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. Merck & Co.
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives
13.12. Coherus Biosciences, Inc.
13.12.1. Company Overview
13.12.2. Product Offerings
13.12.3. Financial Performance
13.12.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers